Sinclair IS Pharma TICKER: SPH     EXCHANGE: L

Sinclair IS Pharma is an international speciality pharma company, with corporate headquarters in London, and operations headquarters in Paris. Creating and developing brand families in different areas of dermatology is the key to Sinclair's growth strategy. The company has an established sales and marketing footprint in the UK, France, Germany, Italy and Spain, and a rapidly growing presence in emerging markets through key strategic partners.


Sinclair IS Pharma Investor Forum Presentation
Published: Jun 11 2014

Chris Spooner, CEO, gives an enlightening and witty presentation on the future of the aesthetics market, the benefits of collagen stimulation over fillers, and what treatments leading celebrities have undergone. 
Sinclair Pharma; Full review of results/license deal/acquisition
Published: Jul 04 2006

  • GCSD purchased in France
  • Decapinol licensed in USA
  • Profitabilty forecast for 2007
Sinclair Pharma; successfully executing strategy
Published: Jan 19 2006

  • Over 30 licensing agreements in FY 2005
  • Italian acquisition contributing over £1m
  • Healthy cash position, bolstered by £7m issue
  • Reassuring Pre Close period update
  • Fair value/ share: 195-202p vs current 135p
Sinclair Pharma; R&D update
Published: Jul 04 2005

Sinclair Pharma's financial year has successfully drawn to an end with an extensive number of regulatory approvals in both the US and EU, 31 commercial agreements signed worldwide over the period, and a company acquisition in Italy.
Sinclair Pharma; Acquisition and product progress
Published: May 25 2005

  • Decapinol approved by FDA
  • Acquisition of Euroderm RDC
  • Good news flow
  • Fair value still seen as 165p a share
Sinclair Pharma; License for change
Published: Jan 14 2005

  • US licence agreement for Atopiclair with Chester Valley Pharmaceuticals
  • Acquisition of Euroderm-RDC SpA
  • First European distribution agreement for Decapinol®
  • Significant enhancement of the company's prospects
  • Fair Value of 165p
Sinclair Pharma; low risk life science business model heading towards profit
Published: Aug 20 2004

  • Low risk business model in emerging life sciences with growth prospects.
  • Nine of the eleven products in the company's portfolio are already registered in the US, EU, or both
  • On our conservative projections Sinclair Pharma should become profitable in 2007.
  • Our fair value estimate of 165p compares with the current share price of 107.5p


Foreign buyers gorging on UK stocks

Document can be downloaded here: UK plc ‘going for a song’

Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers – partly triggered by the June 2016 Brexit result, which sent the £ tumbling and adversely affected the FTSE.

Consequently today, given this trend is unlikely to end anytime soon, we’ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks – covering a broad selection of industries.

What’s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.

According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% – with the figure trending upwards since the global financial crisis.

Happy investing. Published 27th August 2019